Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Ki20227
CHF 0.00
In stock
SYN-1049-M0011 mgCHF 142.00
SYN-1049-M0055 mgCHF 234.00
SYN-1049-M01010 mgCHF 341.00
SYN-1049-M05050 mgCHF 1'171.00
SYN-1049-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | Ki-20227 |
| Product Type | Chemical |
| Properties | |
| Formula | C24H24N4O5S |
| MW | 480.5 |
| CAS | 623142-96-1 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: c-fms | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | SHPFDGWALWEPGS-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Ki20227 is a c-fms tyrosine kinase inhibitor. It has IC(50) values of 2, 12, 451 and 217nM for c-Fms, VEGFR-2, c-Kit and PDGFRβ respectively.
Product References
- A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model: H. Ohno, et al.; Mol. Cancer Ther. 5, 2634 (2006)
- The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model: H. Ohno, et al.; Eur. J. Immunol. 38, 283 (2008)
- M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis: Y. Kubota, et al.; J. Exp. Med. 206, 1089 (2009)
Related Products
